

Press Release

17 June 2009

e-Therapeutics plc
("e-Therapeutics" or "the Company")

Director's shareholding

e-Therapeutics plc (AIM: ETX), the systems biology drug discovery company, announces that on 18 March 2009, the Self Invested Pension Plan of John Cordiner acquired, in aggregate, 5,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at an average price of 34p per share. Following this acquisition, John Cordiner and his Self Invested Pension Plan have in aggregate an interest in 367,060 Ordinary Shares, which represents 0.6 % of the current issued share capital of the Company.

- Ends -

For further information:

e-Therapeutics plc www.etherapeutics.co.uk
Malcolm Young +44 (0) 191 233 1317
malcolm@etherapeutics.co.uk

Nominated Advisor:
WH Ireland
Katy Mitchell +44 (0)113 394 6628
katy.mitchell@wh-ireland.co.uk

Broker:
Cornhill Capital Limited
Tom Whitehead +44 (0) 20 7645 8327
tomw@cornhillcapital.com

Andrew Houchin +44 (0) 20 7743 6468
andrewh@cornhillcapital.com

Media enquiries:

Abchurch www.abchurch-group.com
Heather Salmond Tel: +44 (0) 20 7398 7704
heather.salmond@abchurch-group.com



e-Therapeutics plc

Stephanie Cuthbert
stephanie.cuthbert@abchurch-group.com

Tel: +44 (0) 20 7398 7718

Simone Alves
simone.alves@abchurch-group.com

Tel: +44 (0) 20 7398 7728

Notes to Editors

e-Therapeutics plc is a systems biology drug discovery company. It has developed proprietary computational systems to swiftly and accurately analyse and predict how medicines interact with cells in the body. This optimises the probability of identifying drug candidates with desirable efficacy and low toxicity. The Company applies its novel, systematic approach to three areas of activity:

- discovery of new drugs;
- discovering novel uses for existing drugs; and
- analysis of the interactions between different drugs.

Amongst e-Therapeutics' pipeline of compounds in development are novel antibiotics that have been shown to kill the "superbug" MRSA, and a novel cancer chemotherapy that has been shown to kill malignant cells at safe doses in a very short time. Other candidate therapies in development are targeted at atherosclerosis, asthma and depression. The Company is currently in negotiation with a number of pharmaceutical companies, and is progressing the preclinical and clinical development of these products.

For further information on e-Therapeutics visit www.etherapeutics.co.uk.